Anti-Obesity Medications: What the Science Says About Their Effectiveness, Safety, and Role in Obesity Management

Obesity is a chronic, relapsing, and multifactorial condition that significantly increases the risk of type 2 diabetes, cardiovascular disease, obstructive sleep apnea, osteoarthritis, and certain types of cancer (Blüher, 2019; Bray, Kim, Wilding, & World Obesity Federation, 2017). Global data indicate a steady rise in obesity prevalence across all age groups and socioeconomic strata, making it one of the most pressing public health challenges worldwide (NCD Risk Factor Collaboration (NCD-RisC), 2016).

Although lifestyle interventions—such as nutritional counseling and increased physical activity—remain foundational in obesity treatment, a considerable proportion of individuals do not achieve or maintain clinically meaningful weight loss through these strategies alone (Ryan & Yockey, 2017). In this context, anti-obesity medications have emerged as important tools within a combined therapeutic approach and are now endorsed by several international clinical guidelines (Apovian et al., 2015; Wharton et al., 2020).

Mechanisms of Action and Key Medications

Below, we discuss the key medications approved for obesity treatment, organized by their approval date in the United States, with an emphasis on their mechanisms of action, efficacy, indications, limitations, and adverse effects.

1. Orlistat

Orlistat was approved by the FDA in 1999 and remains one of the most commonly used anti-obesity medications. It acts peripherally by inhibiting gastrointestinal lipases, the enzymes which break down dietary fats. By inhibiting its breakdown, approximately 30% of the dietary fat is not absorbed, leading to weight loss (Torgerson et al., 2004).

Efficacy: Orlistat has been shown to produce modest weight loss, typically ranging from 5-10% of body weight when combined with a reduced-calorie diet. Studies have also demonstrated that it is effective in improving long-term weight maintenance in overweight and obese individuals (Torgerson et al., 2004).

Indications: It is indicated for weight management in overweight and obese individuals, and can also improve associated comorbidities such as hypertension and type 2 diabetes (Rucker et al., 2007).

Limitations: Orlistat’s efficacy is limited by gastrointestinal side effects such as oily stools, flatulence, and fecal incontinence (Rucker et al., 2007).

Adverse Effects: Common side effects include gastrointestinal disturbances, while more serious but rare effects may include liver toxicity (Rucker et al., 2007).

2. Phentermine

Phentermine has been approved for short-term use since the 1950s and remains widely prescribed as an appetite suppressant in the United States. It is a sympathomimetic drug that works by stimulating the release of norepinephrine in the brain, which reduces hunger (Elmaleh-Sachs et al., 2023).

Efficacy: Phentermine is effective for short-term weight loss, typically resulting in a 5-10% reduction in body weight when combined with reduced diet calorie and moderate level exercise (Cosentino et al., 2013).

Indications: It is prescribed for short-term use in obese patients who have not achieved significant weight loss through lifestyle changes alone (Greenway et al., 2009).

Limitations: Due to concerns about cardiovascular safety and the potential for dependency, it is not approved for long-term use in many countries (Grunvald et al., 2022).

Adverse Effects: Common side effects include increased heart rate, elevated blood pressure, insomnia, and nervousness (Elmaleh-Sachs et al., 2023; Grunvald et al., 2022).

3. Naltrexone-Bupropion Combination

The naltrexone-bupropion combination was approved by the FDA in 2014 and acts on the central nervous system by modulating both the hypothalamic appetite-regulation pathway and the mesolimbic dopamine reward system (Greenway et al., 2009).

Efficacy: It has been shown to produce moderate weight loss, with an average reduction of 5-10% of body weight when combined with diet and exercise (Greenway et al., 2009).

Indications: It is particularly beneficial for patients with binge-eating behaviors or poor appetite control and may also help with the emotional and psychological aspects of obesity (Greenway et al., 2009).

Limitations: The weight loss achieved with the naltrexone-bupropion combination is more modest compared to other options such as GLP-1 receptor agonists (Apovian et al., 2015).

Adverse Effects: Common side effects include nausea, constipation, headache, and insomnia. It should be used with caution in patients with a history of seizures or eating disorders (Apovian et al., 2015).

4. GLP-1 Receptor Agonists (Liraglutide and Semaglutide)

GLP-1 receptor agonists, such as liraglutide (approved in 2014) and semaglutide (approved in 2021), have become widely used in the treatment of obesity. These medications mimic the incretin hormone GLP-1, enhancing satiety, delaying gastric emptying, and reducing appetite (Pi-Sunyer et al., 2015; Wilding et al., 2021).

Efficacy: GLP-1 agonists are among the most effective anti-obesity medications, with semaglutide demonstrating superior efficacy in promoting weight loss—up to 15-20% of body weight in clinical trials (Wilding et al., 2021).

Indications: They are indicated for weight loss in patients with obesity or patients who are overweight and who have comorbidities such as type 2 diabetes (Pi-Sunyer et al., 2015; Wilding et al., 2021).

Limitations: While highly effective, these medications require injections (daily for liraglutide and weekly for semaglutide) and can be expensive (Wilding et al., 2021).

Adverse Effects: Common side effects include nausea, diarrhea, and abdominal pain. They should be used cautiously in patients with a history of gastrointestinal issues or thyroid cancer (Pi-Sunyer et al., 2015).

The Role of Clinical Nutrition

Nutritional intervention is essential in any obesity treatment plan, including when medications are used. Dietitians play a crucial role in recommending adjustments to caloric intake, preventing nutrient deficiencies (e.g., fat-soluble vitamins in orlistat users), preserving lean mass during weight loss, and promoting autonomous, sustainable eating behaviors (Lean et al., 2018).

Moreover, the dietitian is well-positioned to tailor dietary strategies to minimize medication side effects and support long-term adherence to a healthy lifestyle. For example, patients using GLP-1 agonists may benefit from smaller, more frequent meals to reduce nausea, while those on orlistat should limit fat intake and consider vitamin supplementation.

Studies consistently show that combining medication with structured nutrition and behavioral therapy results in greater weight loss and improved long-term outcomes (Ryan & Yockey, 2017). Structured nutrition therapy typically includes a balanced, calorie-controlled eating plan that emphasizes whole foods, portion control, and nutrient-dense options (Griffiths et al., 2021). Behavioral therapy often involves cognitive strategies, such as goal setting, self-monitoring, and identifying triggers for overeating, alongside motivational interviewing techniques to foster sustained behavior change and long-term weight management (Barnes & Ivezaj, 2015; Wadden & Butryn, 2003).

Conclusion

Anti-obesity medications represent a significant advancement in the clinical management of obesity, offering promising results when lifestyle modification alone is insufficient. However, long-term weight management requires more than just medication. It requires  a multidisciplinary approach grounded in scientific evidence, individualized care, and ongoing professional support.

References

Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., … & Endocrine Society. (2015). Pharmacological management of obesity: An endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 100(2), 342–362. doi:10.1210/jc.2014-3415

Barnes, R. D., & Ivezaj, V. (2015). A systematic review of motivational interviewing for weight loss among adults in primary care. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity, 16(4), 304–318. doi:10.1111/obr.12264

Blüher, M. (2019). Obesity: Global epidemiology and pathogenesis. Nature Reviews. Endocrinology, 15(5), 288–298. doi:10.1038/s41574-019-0176-8

Bray, G. A., Kim, K. K., Wilding, J. P. H., & World Obesity Federation. (2017). Obesity: A chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity, 18(7), 715–723. doi:10.1111/obr.12551

Cosentino, G., Conrad, A. O., & Uwaifo, G. I. (2013). Phentermine and topiramate for the management of obesity: A review. Drug Design, Development and Therapy, 7, 267–278. doi:10.2147/DDDT.S31443

Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023). Obesity management in adults: A review. The Journal of the American Medical Association, 330(20), 2000–2015. doi:10.1001/jama.2023.19897

Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., … & NB-201 Study Group. (2009). Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. The Journal of Clinical Endocrinology and Metabolism, 94(12), 4898–4906. doi:10.1210/jc.2009-1350

Griffiths, L. A., Douglas, S. M., & Raynor, H. A. (2021). The role of structure in dietary approaches for the treatment of pediatric overweight and obesity: A critical review. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity, 22(9), e13266. doi:10.1111/obr.13266

Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., … & AGA Clinical Guidelines Committee. (2022). AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology, 163(5), 1198–1225. doi:10.1053/j.gastro.2022.08.045

Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., … & Taylor, R. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial. Lancet, 391(10120), 541–551. doi:10.1016/S0140-6736(17)33102-1

NCD Risk Factor Collaboration (NCD-RisC). (2016). Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet, 387(10026), 1377–1396. doi:10.1016/S0140-6736(16)30054-X

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., … & SCALE Obesity and Prediabetes NN8022-1839 Study Group. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. The New England Journal of Medicine, 373(1), 11–22. doi:10.1056/NEJMoa1411892

Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007). Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ (Clinical Research Ed.), 335(7631), 1194–1199. doi:10.1136/bmj.39385.413113.25

Ryan, D. H., & Yockey, S. R. (2017). Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Current Obesity Reports, 6(2), 187–194. doi:10.1007/s13679-017-0262-y

Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. doi:10.2337/diacare.27.1.155

Wadden, T. A., & Butryn, M. L. (2003). Behavioral treatment of obesity. Endocrinology and Metabolism Clinics of North America, 32(4), 981–1003, x. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/14711071

Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., … & Wicklum, S. (2020). Obesity in adults: A clinical practice guideline. Journal de l’Association Medicale Canadienne [Canadian Medical Association Journal], 192(31), E875–E891. doi:10.1503/cmaj.191707

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. doi:10.1056/NEJMoa2032183